Tadalafil Once a Day for Men with Erectile Dysfunction: Is It Superior than On-Demand Administration?

Dimas Tri Prasetyo, Putu Angga Risky Raharja, Ben Julian Mantiri, David Ralph Lienhardt Ringoringo, Irham Arif Rahman, Jody Felizio, Made Parulian Tambunan, Syifa Fauziah Fadhly, Harrina Erlianti Rahardjo

Abstract


Background: Tadalafil is a PDE5I which has been licensed for the treatment of erectile dysfunction (ED) since 2003, is effective from 30 minutes after administration and its efficacy is maintained for up to 36 hours. More recently, it is also given OAD in a lower dose to allow spontaneous sexual activities. However, whether OAD administration is more effective than PRN administration in improving the EF is yet to be established. This study aimed to evaluate whether OAD administration of tadalafil leads to a better improvement of erectile function (EF) in patients with erectile dysfunction (ED) compared to PRN administration. Methods: literature search of electronic database was performed through Medline, Scopus, Cochrane Library, and CINAHL databases. Cochrane Risk of Bias Tool was then employed to assess the risk of bias in each study. Results: initial literature search resulted in 231 hits, but only four studies were included in final selection. Based on our judgements, the study by Kang et al. was the most applicable in our clinical setting. This study showed that subjects who received tadalafil OAD had statistically significant higher increases of mean IIEF-EF (6.5 (SD 4.5) vs 4.9 (SD 4.2), p=0.032), proportion of “yes” responses to SEP-2 (81.8% vs 64.7%, p=0.025), and proportion of “yes” responses to SEP-3 (77.3% vs 60.3%, p=0.034). Conclusion: administration of tadalafil OAD leads to a better improvement of EF compared to PRN administration.

Keywords


Tadalafil; once-a-day; erectile dysfunction; IIEF.

References


Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. 2017.

Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinklay JB. Impotence and its medical and physiological correlates: Results of the massacheusetts male aging study. J Urol. 1994;151:54–61.

Nicolosi A, Glasser DB, Kim SC, Marumo K, Laumann EO. Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of asian countries. BJU Int. 2005;95(4):609–14.

Suzuki E, Nishimatsu H, Oba S, Takahashi M, Homma Y. Chronic kidney disease and erectile dysfunction. World J Nephrol. 2014;3(4):220–9.

Papadopoulou E, Varouktsi A, Lazaridis A, Boutari C, Doumas M. Erectile dysfunction in chronic kidney disease: From pathophysiology to management. World J Nephrol. 2015;4(3):379–87. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4491929&tool=pmcentrez&rendertype=abstract.

Hatzimouratidis K, Eardley I, Giuliano F, et al. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–14. Available from: http://uroweb.org/wp-content/uploads/14-Male-Sexual-Dysfunction_LR.pdf.

Curran MP, Keating GM. Tadalafil. Drugs. 2003;63:2203–12.

Buvat J, Büttner H, Hatzimouratidis K, et al. Adherence to initial PDE-5 inhibitor treatment: Randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med. 2013;10(6):1592–602.

Kang DH, Lee JY, Chung JH, et al. Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract. 2012;66(8):813–20.

McMahon C, Kloner RA, Hutter AM, Porst H. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2(3):415–27.

Rubio-Aurioles E, Porst H, Kim ED, et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012;9(5):1418–29.

Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med. 2009;6(7):2039–48.

Peng Z, Yang L, Dong Q, Wei Q, Liu L, Yang B. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: A systematic review and meta-analyses. Urol Int. 2017;(37):343–52.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Acta Medica Indonesiana